“The molecule’s the thing:” the promise of molecular modeling and dynamic simulations in aiding the prioritization and interpretation of genomic testing results [version 2; referees: 2 approved, 1 approved with reservations]

• Main Authors: Gavin R. Oliver, Michael T. Zimmerman, Eric W. Klee, Raul A. Urrutia
• Format: Article
• Language: English
• Published: F1000 Research Ltd 2016-06-01
• Series: F1000Research
• Subjects: Methods for Diagnostic & Therapeutic Studies; Structural Genomics; Theory & Simulation
• Online Access: http://f1000research.com/articles/5-766/v2

Clinical genomics is now a reality and lies at the heart of individualized medicine efforts. The success of these approaches is evidenced by the increasing volume of publications that report causal links between genomic variants and disease. In spite of early success, clinical genomics currently faces significant challenges in establishing the relevance of the majority of variants identified by next generation sequencing tests. Indeed, the majority of mutations identified are harbored by proteins whose functions remain elusive. Herein we describe the current scenario in genomic testing and in particular the burden of variants of uncertain significance (VUSs). We highlight a role for molecular modeling and molecular dynamic simulations as tools that can significantly increase the yield of information to aid in the evaluation of pathogenicity. Though the application of these methodologies to the interpretation of variants identified by genomic testing is not yet widespread, we predict that an increase in their use will significantly benefit the mission of clinical genomics for individualized medicine.